https://www.selleckchem.com/pr....oducts/ly3023414.htm
For ABA-1L versus TNFi-1L, ΔPMPM by ACR50 response was -11,715 JPY and by CDAI and SDAI remission 11,602 JPY and 47,003 JPY, respectively. Corresponding costs for ABA-1L were lower for all outcome parameters versus those for ABA-2L+. Scenario analyses showed that ABA-1L was cost-effective over TNFi-1L in patients 65 years for any outcome. Furthermore, ABA-1L was cost-effective over ABA-2L+ for all outcomes in patients with age 65 years, disease duration 5 years and J-HAQ ≥1.5. ABA-1L demonstrated a favourable cost-effectiv
Beğen
Yorum Yap
Paylaş
